A phase 1 study to evaluate the safety and LDL cholesterol –lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9
ConclusionsOverall, RG7652 elicited substantial and sustained dose‐related LDL‐C reductions with an acceptable safety profile and minimal immunogenicity.
Source: Clinical Cardiology - Category: Cardiology Authors: Amos Baruch, Diana Luca, Robert S. Kahn, Kyra J. Cowan, Maya Leabman, Nageshwar R. Budha, Cecilia P.C. Chiu, Yan Wu, Daniel Kirchhofer, Andrew Peterson, John C. Davis Jr, Whittemore G. Tingley Tags: CLINICAL INVESTIGATIONS Source Type: research
More News: Atorvastatin Calcium | Cardiology | Cholesterol | Heart | Lipitor | Statin Therapy | Study | Toxicology | Zivast